Principal Investigator
Hadar Lev-Tov
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20231375
Clinical Trial Summary
A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participant With Moderate to Severe Hidradenitis Suppurativa
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other